Table 1 Clinical summary and follow-up.
Case | Age (y)/Sex | Primary site | Size (cm) | Initial Resection Margin Status | Recurrence/Metastasis | Treatment | Outcome | Follow-up period (months) |
|---|---|---|---|---|---|---|---|---|
1 | 62/M | Anterior mediastinum | 12.90 | Negative | Chest wall (local recurrence) | Neoadjuvant gemcitabine/docetaxel, surgical resection, AIM, doxorubicin, nivolumab/ipilimumab | AWD | 52 |
2 | 24/F | Posterior/paraspinal mediastinum | 18.00 | Positive | T1-T3 spine metastases | Surgical resection, AIM | DOD | 15 |
3 | 68/F | Paraesophageal mass | 12.00 | Positive | Pleural & lung (local recurrence) | Surgical resection, gemcitabine, docetaxel, olaratumab | DOD | 21 |
4 | 52/F | Posterior/paraspinal mediastinum centered at T3-T4 and borders aortic arch, esophagus, vertebra and ribs | 17.50 | Negative | Pleural & lung (local recurrence) | Surgical resection, eribulin, doxetaxel/gemcitabine, pazopanib | AWD | 49 |
5 | 30/M | Anterior mediastinal pleural-based mass involving right supradiaphragmatic fat and invading right anterior chest wall, compressing superior vena cava and right atrium | 13.50 | Positive | Kidney metastasis | Surgical resection, unknown | AWD | 14 |
6 | 10/M | Orbital Floor | 4.80 | N/A | Femur & liver metastases | Ifosfamide, eribulin, radiation therapy, doxorubicin, olaratumab | DOD | 22 |
7 | 34/M | Left upper lung lobe paramediastinal mass | 8.00 | Negative | Pleural & paraspinal (local recurrence) | Neoadjuvant AIM, resection, eribulin, trabectedin | DOD | 14 |
8 | 22/F | Posterior lower mediastinum extending from left inferior pulmonary vein to upper left retroperitoneum, encasing lower thoracic aorta and renal artery | 11.40 | Positive | Sacrum and T8 epidural metastases | Neoadjuvant AIM and radiation therapy, surgical resection, doxorubicin, dacarbazine, eribulin | DOD | 52 |
